ERA

Download the full-sized PDF of Prevention and treatment of Age-related Macular Degeneration (AMD)Download the full-sized PDF

Analytics

Share

Permanent link (DOI): https://doi.org/10.7939/R3007H

Download

Export to: EndNote  |  Zotero  |  Mendeley

Communities

This file is in the following communities:

Graduate Studies and Research, Faculty of

Collections

This file is in the following collections:

Theses and Dissertations

Prevention and treatment of Age-related Macular Degeneration (AMD) Open Access

Descriptions

Other title
Subject/Keyword
clinical trial
macular degeneration
drusen
DHA
OMEGAlberta Study
Type of item
Thesis
Degree grantor
University of Alberta
Author or creator
Dornstauder, Blake
Supervisor and department
Sauve, Yves (Ophthalmology)
MacDonald, Ian (Ophthalmology)
Examining committee member and department
Allison, Ted (Biological Sciences)
MacDonald, Ian (Ophthalmology)
Sauve, Yves (Ophthalmology)
Department
Medical Sciences - Ophthalmology
Specialization

Date accepted
2011-01-11T20:43:34Z
Graduation date
2011-06
Degree
Master of Science
Degree level
Master's
Abstract
Age-related macular degeneration (AMD) is the leading cause of Government-registered blindness in the elderly of the Western world and has two forms: wet and dry. No current AMD therapies are curative, and most are provided after retinal damage from the disease has already occurred (to preserve what is left of the retina). We have constructed a multi-factorial Phase II randomized, controlled clinical trial, titled: “Omega-3 docosahexaenoic acid(DHA) and eicosapentaenoic acid (EPA) nutritional supplementation to delay the progression of age-related macular degeneration (AMD): The OMEGAlberta Study”. Each day, participants in the experimental arm of this study will receive 600mg DHA and 1200mg EPA, plus Vitalux AREDS antioxidant formula. Based on the physicochemical properties of DHA, EPA, and Vitalux, our aim is to delay the 5-year incident rate of progression of intermediate dry AMD to wet AMD. Several tests will be performed, not only to quantify the incident rate of progression of AMD, but also to gain insight of the physiological mechanisms behind the supplements being provided. If the supplements are proven to delay AMD progression, this knowledge should be implemented by changes in health services and policy relating to public education and the treatment of AMD.
Language
English
DOI
doi:10.7939/R3007H
Rights
License granted by Blake Dornstauder (blake@ualberta.ca) on 2011-01-11T18:23:32Z (GMT): Permission is hereby granted to the University of Alberta Libraries to reproduce single copies of this thesis and to lend or sell such copies for private, scholarly or scientific research purposes only. Where the thesis is converted to, or otherwise made available in digital form, the University of Alberta will advise potential users of the thesis of the above terms. The author reserves all other publication and other rights in association with the copyright in the thesis, and except as herein provided, neither the thesis nor any substantial portion thereof may be printed or otherwise reproduced in any material form whatsoever without the author's prior written permission.
Citation for previous publication

File Details

Date Uploaded
Date Modified
2014-05-01T01:39:21.181+00:00
Audit Status
Audits have not yet been run on this file.
Characterization
File format: pdf (Portable Document Format)
Mime type: application/pdf
File size: 4337195
Last modified: 2015:10:12 12:47:30-06:00
Filename: Dornstauder_Blake_Spring2011.pdf
Original checksum: 15cabeee854d0cb30dc21350fb3cc0ff
Well formed: true
Valid: false
Status message: Invalid page tree node offset=86234
Status message: Outlines contain recursive references.
File title: Title Page
File title: Microsoft Word - Title Page
File author: Blake
Activity of users you follow
User Activity Date